Richard DiMarchi, PhD

Dr. DiMarchi became a director in July 2014 following of the acquisition of Assembly Pharmaceuticals, which he co-founded and served as a founding director. Dr. DiMarchi currently holds the Cox Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University (currently on leave of absences until January 2020) and serves as Vice President of Research at Novo Nordisk Research Labs. Dr. DiMarchi was a co-founder and board member of biotechnology companies Ambrx, and Marcadia Biotech, a founder of Calibrium LLC, and advisor to Twilight Ventures. Dr. DiMarchi previously served as a director of Isis and Millennium BioTherapeutics, as well as board member of the biotechnology trade group BIO. Dr. DiMarchi contributed significantly to the discovery of the first insulin analog, Humalog®, and to the commercial development of major pharmaceutical products such as Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo® and Evista®. He is the recipient of numerous awards and has been inducted into the National Inventors Hall of Fame and the National Academy of Medicine. Dr. DiMarchi received a BS with honors from Florida Atlantic University and a PhD in Biochemistry from Indiana University. He completed postdoctoral studies at The Rockefeller University.

Independent Director